Multidomain lifestyle intervention

Studies of multidomain lifestyle intervention in people

82 studies gave multidomain lifestyle intervention to people and measured what changed

What changedDesignPeopleSource

up: Improves social support

up: Improves health-related quality of life

down: Prevents depressive symptoms

Randomized trial8 weeks30 peopleMild cognitive impairmentNeuroscience, Oct 31, 2026

up: Increases seattle Angina Questionnaire summary scoreAdjusted between-group difference +7.10 points (95% CI 0.87–13.30; p=0.026)

Randomized trial12 months123 peopleMenANOCAESC Congress 2026 abstract, Oct 26, 2026

no change: Has no effect on body weightb = -0.30, 95% CI: -0.51; 1.11

no change: Has no effect on motivation and confidence regarding weight lossOR = 1.07, 95% CI: 0.78; 1.46

Randomized trial24 months678 peopleBoth60–77 years; mean 68.9 years (SD 4.8)Older adults with overweight or obesity at risk of dementiaBMC geriatrics, Oct 15, 2026

no change: Has no effect on AD plasma biomarker trajectories

Randomized trialtwo years1,260 people46.9% were womenmean age 68.8 ± 4.7 yearsCommunity-dwelling older adults at risk of dementiamedRxiv, Oct 6, 2026

up: Improves gait speed0.06 m/s (95% CI, 0.01 to 0.12)

Randomized trial18 months433 peopleBoth65-85 yearsOlder adults; mild cognitive impairment, High DVS groupClinical nutrition ESPEN, Sep 29, 2026

up: Improves montreal Cognitive Assessment0.58 points, 95% CI 0.03–1.13

no change: Has no effect on trail Making Test0.16 s (95% CI −5.07 to 5.40)

no change: Has no effect on skeletal muscle mass index

Randomized trial6 months355 peopleBothaged 65 years or olderRisk-enriched community-dwelling older populationEClinicalMedicine, Sep 23, 2026

up: Improves diet scoreBeta 1.67, 95% CI 0.61;2.73, PFDR=0.01

up: Improves sleep scoreBeta −1.80, 95% CI −2.79;-0.81, PFDR=0.005

no change: Has no effect on working memory performance

Randomized trialsix months102 people60–75 yearsOlder adults; at risk for cognitive decline and dementiamedRxiv, Jul 29, 2026

up: Improves cognitive functionbetween-group difference, 4.17 points; 95% CI 1.92-6.43

Randomized trial24 weeks277 peopleBoth60-85 yearsOlder adults; mild cognitive impairmentNeurology, Jul 20, 2026

up: Improves global cognitive functionmean between-group difference 0.11 SD per year (95% CI 0.06-0.15; p<0.0001)

Randomized trial2 years1,065 peopleBoth60-77 yearsOlder adultsLancet (London, England), Jul 13, 2026

no change: Has no effect on white matter hyperintensity volumeβ = 0.002; SE = 0.016

Randomized trialup to 24 months959 peopleBoth60 to 79 yearsOlder adultsJAMA network open, Jul 1, 2026

down: Lowers the risk of cognitive impairmentHR = 0.64 [0.46,0.89]

no change: Has no effect on cognitive impairmentHR = 0.98 [0.85,1.16]

up: Raises the risk of cognitive impairmentHR = 1.40 [1.01,1.93]

Randomized trial10-year intervention, 12-14 years post-trial follow-up3,655 peopleBaseline BMI 25-29 kg/m2 (overweight)Alzheimer's & dementia : the journal of the Alzheimer's Association, Jul 1, 2026

no change: Has no effect on global cognitive composite

Randomized trial2 years983 peopleBoth60 to 79 yearsOlder adultsJAMA neurology, Apr 21, 2026

down: Decreases frailty index-0.014 (95% CI -0.019, -0.008)

up: Improves cognitive function0.076 [0.038, -0.114]

Randomized trial24 months2,111 peopleBoth60-79 years of ageOlder adults at risk for cognitive decline due to established demographic, lifestyle, family history, and cardiometabolic factorsThe journals of gerontology. Series A, Biological sciences and medical sciences, Apr 7, 2026

down: Decreases blood pressureto approximately 120/80 mmHg

up: Increases physical activity

Trialeleven weeks12 peopleBoth50–65 yearsMidlife adults; Older adults; hypertensionAPJAET - Journal ay Asia Pacific Journal of Advanced Education and Technology, Mar 16, 2026

down: Decreases total cholesterol-24.23 mg/dL (95% CI -28.25 to -20.22)

down: Decreases LDL cholesterol-14.41 mg/dL (95% CI -18.36 to -10.45)

up: Increases HDL cholesterol+7.04 mg/dL (95% CI 5.76-8.31)

Randomized trial24 months1,671 peopleBothmean age 40.8 yearsMidlife adults; General populationJournal of clinical lipidology, Mar 13, 2026

down: Decreases trait impulsivitymean z-score change -0.26 [-0.49, -0.03]

down: Decreases global impulsivitymean z-score change -0.28 [-0.52, -0.03]

down: Decreases behavioral impulsivitymean z-score change -0.28 [-0.54, -0.02]

Randomized trial1 year306 peopleBothmean 65.0 yearsOlder adults; overweight or obesity and metabolic syndromePsychotherapy and psychosomatics, Feb 19, 2026

down: Decreases frailty−2.5 [−2.9, −2.0] points

up: Improves grip strength

up: Improves gait speed

Randomized trial24 weeks47 peopleage ≥ 70Community‐dwelling frail older adultsAging cell, Feb 1, 2026

up: Improves cognitive functionadjusted mean difference 0.06 (95% CI -0.00 to 0.13), p=0.055

Randomized trial24 months635 peopleOlder adults; in older adults with subjective cognitive decline or mild cognitive impairmentAAIC 2025 abstract, Dec 23, 2025

up: Improves cognitive functionfrom 73.94 to 82.32

Trial60-75 yearsOlder adults; mild cognitive impairmentAAIC 2025 abstract, Dec 23, 2025

up: Improves cognitive functionβ = 5.93, p = 0.008

Trial284 peopleBothHigh-PRS groupAAIC 2025 abstract, Dec 23, 2025

up: Improves lifestyle adherencep = 0.005

up: Improves cognitive functionp = 0.003

Randomized trial2 years1,259 people60-77 yearsOlder adults; at risk of dementiaAAIC 2025 abstract, Dec 23, 2025

up: Increases Blautia abundancep = 0.0132

Trial6 months27 peopleOlder adults; Patient cohortsAAIC 2025 abstract, Dec 23, 2025

up: Improves cognitive functiontime*group*ApoE4 interaction p = 0.035

Review of trials>=60 yrsOlder adults; ApoE4 carriers vs non-carriersAAIC 2025 abstract, Dec 23, 2025

no change: Has no effect on cognitive function22.8 ± 3.1 to 23.1 ± 3.5

up: Improves food diversity7.5 ± 2.8 to 8.4 ± 2.5, p = 0.008

Trial12 months80 people65–86Older adultsAAIC 2025 abstract, Dec 23, 2025

up: Improves cognitive functionES range 0.21 to 0.41

Randomized trial3 to 6 months165 peopleBothmean 70 yearsOlder adults; MCI or SCD and 2 or more dementia risk factorsAAIC 2025 abstract, Dec 23, 2025

down: Protects against cognitive frailtyRR: 1.88; 95% CI: 1.24-2.84; p =.003

up: Increases cognitive frailty reversalbetween-group difference −16.6 percentage points; 95% CI: −30.4 to −2.8; p =.018

Randomized trial2-year1,200 people550 (46%) were femalemean age of participants was 69 yearsFinnish adults, aged 60-77 years, recruited from the general population with elevated risk for dementiaThe journals of gerontology. Series A, Biological sciences and medical sciences, Dec 16, 2025

down: Decreases body weight-6.5%, p<0.005

down: Decreases Framingham risk score-7.6%, p<0.001

down: Decreases atherogenic index of plasma40.0% to 33.6%

Trialone-year271 peopleBoth30 to 75 yearsMidlife adults; Older adults; obesityAHA Scientific Sessions 2025 abstract, Nov 3, 2025

up: Increases Life's Essential 8+3.3 points (95% CI: 2.1, 4.6)

down: Decreases perceived stress scale-1.9 points (95% CI: -2.7, -1.2)

Randomized trial24 weeks198 peopleMenmean 54 yearsMidlife adultsAHA Scientific Sessions 2025 abstract, Nov 3, 2025

up: Improves cognitive functionZ score difference = 0.107, 95% CI = 0.016 to 0.198

down: Decreases systolic blood pressureAMD = −5.11, 95% CI = −9.16 to −1.07

up: Improves HDL cholesterolAMD = 2.51, 95% CI = 0.53 to 4.49

Randomized trial18 month432 peopleaged 65 to 85 yearsIndividuals aged 65 to 85 years diagnosed with mild cognitive impairmentAlzheimer's & dementia : the journal of the Alzheimer's Association, Nov 1, 2025

down: Decreases body weight77.0 [68.0–87.0] kg to 75.9 [67.2–85.7] kg

down: Decreases body mass index26.8 [24.4–29.8] to 26.4 [24.1–29.4]

down: Decreases waist circumference95 [88.5–103] to 93 [86–101] cm

Trial90 days2,300 people18 to 59Broad group of employees aged 18 to 59 in the UAEInternational journal of environmental research and public health, Oct 21, 2025

up: Improves cognitive functionfrom 21.9 ± 2.9 to 23.3 ± 3.8, p = 0.007

Trial12 months37 peopleBothmean age, 78.6 yearsOlder adults; mild cognitive impairmentJournal of Alzheimer's disease : JAD, Sep 1, 2025

up: Improves cognitive function0.045 (0.004 to 0.087)

Randomized trial2-year1,177 peopleWomen60-77 yearsOlder adults; higher-risk females (AD-GRS above median)Brain : a journal of neurology, Aug 1, 2025

up: Improves cognitive functionZ-score difference: +0.335, 95% CI: +0.045 to +0.624

no change: Has no effect on cognitive functionZ-score difference: -0.121, 95% CI: -0.353 to +0.110

Randomized trial18 months90 people70-85 yearsOlder adults; in older adults with type 2 diabetes, mild cognitive impairment, and white matter hyperintensitiesDiabetes, obesity & metabolism, Jul 14, 2025

up: Improves cognitive function+2.5, 95% CI: 1.1-3.9

down: Decreases frailty-1.2, 95% CI: -1.7 to -0.7

down: Decreases depressive symptoms-4.3, 95% CI: -5.6 to -3.0

Trial6 months39 people≥ 60 yearsOlder adults; type 2 diabetesADA Scientific Sessions 2025 abstract, Jun 13, 2025

up: Improves gait speed0.08 m/s, 95 % CI: 0.03 – 0.13

up: Improves grip strength

down: Decreases frailty−0.21, 95 % CI: −0.38 - −0.03

Randomized trial12 months1,082 peoplemean age 75.1 yearsCommunity-dwelling older adults with impaired instrumental activities of daily living, slow gait speed or subjective memory declinesThe journal of prevention of Alzheimer's disease, Jun 12, 2025

down: Lowers the risk of pre-frailty/frailty-9.6 percentage points (95% CI -16.6-(-2.6))

Randomized trial2 years (active intervention period), with follow-up to 11 years1,201 people551 (46%) were womenmean age 69.3 yearsFinnish older adults aged 60-77 years with elevated risk for dementia based on CAIDE risk scoreJournal of the American Geriatrics Society, May 30, 2025

up: Improves physical activity

up: Improves diet quality

no change: Has no effect on self-evaluated health

Randomized trialtwo-year1,259 peopleaged 60–77 yearsCommunity-dwelling older participants aged 60–77 years at the beginning of the study and manifesting an elevated risk for developing dementia based on the CAIDE (Cardiovascular Risk Factors, Aging and Dementia) dementia risk scoreBMC geriatrics, May 3, 2025

down: Decreases subjective cognitive declinep = 0.026

Randomized trial18 months196 peopleolder adultsOlder adults; normal cognitionJournal of Alzheimer's disease : JAD, Apr 22, 2025

up: Increases physical activityOR 1.87, 95% CI 1.36–2.55

Randomized trial2 years1,259 people60–77 yearsOlder individuals at risk for dementiaBMC geriatrics, Mar 29, 2025

up: Improves quality of life

up: Improves depressive symptoms

no change: Has no effect on social inclusion

Randomized trialBoth60-77 yearsOlder adultsJournal of Alzheimer's disease : JAD, Feb 9, 2025